Infectious diseases (London, England)最新文献

{"title":"Body mass index and prognosis of infective endocarditis.","authors":"Raquel Frías-García, Patricia Muñoz García, Marina Machado Vilchez, Gregorio Cuerpo Caballero, Raquel Rodríguez-García, Ma Ángeles Rodríguez-Esteban, Ma Carmen Fariñas-Álvarez, José M Miró Meda, Andrea Gutiérrez Villanueva, Guillermo Ojeda-Burgos, Ane Josune Goikoetxea-Agirre, Marina Bernal Palacios, Manuel Martínez-Sellés","doi":"10.1080/23744235.2025.2481914","DOIUrl":"10.1080/23744235.2025.2481914","url":null,"abstract":"<p><strong>Background and objectives: </strong>Malnutrition is associated with prognosis in several heart diseases, but there is little information in patients with infective endocarditis (IE). Our objective was to assess the influence of body mass index (BMI) on the prognosis of IE.</p><p><strong>Methods: </strong>National registry of patients with definite or probable IE from 2008 to 2021, comparing in-hospital and 1-year mortality according to BMI.</p><p><strong>Results: </strong>From 3645 patients, 91 (2.5%) were underweight, 1432 (39.3%) had normal weight, 1503 (41.2%) were overweight, and 619 (17.0%) had obesity. The median age was lowest in the underweight group (51 vs. >66 years in the other groups, <i>p</i> < 0.001). Patients with underweight/normal weight had an inferior age-adjusted Charlson comorbidity score than those with overweight/obesity (4 vs. 5, <i>p</i> < 0.001). Tricuspid IE was common in patients with underweight (15.4%), while in other groups its prevalence was <6%, <i>p</i> < 0.001. In-hospital and 1-year mortality were respectively: underweight (26.4% and 34.1%), normal weight (19.9% and 25.8%), overweight (22.4% and 27.8%), and obesity (27.8% and 32.5%), both <i>p</i> values ≤0.01. In multivariate analysis, underweight showed a trend for an association with in-hospital mortality (odds ratio 1.67; 95% confidence interval 0.93-3.01 <i>p</i> = 0.09) and a significant association with 1-year mortality (hazard ratio 1.94; 95% confidence interval 1.14-3.31; <i>p</i> = 0.015).</p><p><strong>Conclusions: </strong>The prognosis of IE in patients with underweight and obesity is worse than in those with normal weight or overweight, and low weight is an independent predictor of 1-year mortality.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"793-800"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143766075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A group with emerging potential in the clinical and public health realms: the genus <i>Providencia</i>.","authors":"J Michael Janda","doi":"10.1080/23744235.2025.2509007","DOIUrl":"10.1080/23744235.2025.2509007","url":null,"abstract":"<p><strong>Background: </strong>The genus <i>Providencia</i> is increasingly being recognized as an important human pathogen. Previously a member of the family <i>Enterobacteriaceae</i> but now reclassified into the family <i>Morganellaceae</i> along with <i>Morganella</i> and <i>Proteus</i>, the phylogenetic depth of this clade has expanded from 3 species in its inception to 12 as of 2025. Recent clinical and epidemiologic data provide convincing evidence that <i>P. alcalifaciens</i> causes gastroenteritis and there is also increasing recognition of carbapenem-resistant strains of <i>P. stuartii</i> and <i>P. rettgeri</i> causing serious infections in hospital settings.</p><p><strong>Objective and methods: </strong>Since 2000, no comprehensive review of this genus has been published detailing taxonomic changes, ecological associations, emerging disease trends, pathogenicity and diagnostic modalities useful in detecting and typing providenciae. The objective of this article is to provide a current review and update of recent publications (PubMed, ScienceDirect, Google Scholar, Scopus^®) post-2000 and to summarize results and conclusions to date on this increasingly important genus.</p><p><strong>Results: </strong>Many reports have now been published describing human cases of enteritis and major outbreaks of gastroenteritis attributed to <i>P. alcalifaciens</i> and supported by multiple epidemiologic lines of evidence including typing methods (serology, molecular), in vivo immune responses, and case-controlled investigations. Similar disease syndromes have also been reported in dogs and pigs with one national canine outbreak of haemorrhagic diarrhoea reported from Norway in 2021. In addition, increasing drug resistance has been noted in both <i>P. stuartii</i> and <i>P. rettgeri</i> leading to the worldwide discovery of multi-, extensive-, and pan-resistant isolates causing disease which presents diagnostic issues in the laboratory and therapeutic challenges.</p><p><strong>Conclusion: </strong>The analysis reveals that providenciae are increasingly being implicated as important causes of intestinal and systemic disease. This is supported by a ten-fold increase in the number of <i>Providencia</i> studies listed in PubMed between 2000 and 2024. Methods need to be developed in the microbiology laboratory to recognize \"pathogenic\" strains of <i>P. alcalifaciens</i> that produce enteritis from commensal isolates. Emerging antimicrobial resistance needs to be detected early, monitored, and controlled to avoid further dissemination. New infection control prevention procedures need to be advanced and assessed for usefulness in medical care facilities.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"699-725"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of antibiotic consumption and resistance in intensive care units in France before and during the COVID-19 pandemic.","authors":"Alain Lepape, Anais Machut, Christelle Elias, Anne Savey, Jean-Christophe Richard, Céline Monard, Céline Guichon, Neven Stevic, Melanie Colomb-Cotinat, Arnaud Friggeri","doi":"10.1080/23744235.2025.2540008","DOIUrl":"https://doi.org/10.1080/23744235.2025.2540008","url":null,"abstract":"<p><p>The COVID pandemic significantly impacted intensive care unit (ICU) antibiotic con sumption (AMC) and resistance (AMR). This study examines these effects over a 6-year period in 6 French ICUs.</p><p><strong>Objectives: </strong>To evaluate the impact of the COVID pandemic on AMC and AMR in ICUs, focusing on changes in consumption patterns and bacterial resistance profiles.</p><p><strong>Methods: </strong>Data were prospectively collected from 3 university hospitals, covering 6ICUs. The study compared two periods: before (2017-2019: befPAND period) and during (2020-2022: perPAND period) the pandemic. Antibiotic consumption was measured using Defined Daily Doses (DDD) globally per unit and per 1,000 patient-days in each unit. Antibiotic resistance was assessed from bacterial cultures from selected clinical cultures taken from ICU patients. Statistical analysis compared trends between the two periods.</p><p><strong>Results: </strong>Total antibiotic consumption of all units increased by 28% during the pandemic period, but DDD/1000 patient-days of all units remained stable. There was an increase in the use of broad-spectrum antibiotics, particularly those classified as 'Reserve' by the WHO (5.6% to 9.6%, <i>p</i> < 0.0001).The number of positive cultures increased in the perPAND period for <i>Staphylococcus epidermidis</i>, <i>Enterobacter</i> sp., and <i>Pseudomonas aeruginosa</i>. Resistance levels showed an increase in <i>Enterococcus</i> species, <i>Pseudomonas aeruginosa,</i> and <i>Stenotrophomonas maltophilia</i>, while methicillin-resistant <i>Staphylococcus aureus</i> and 3rd generation cephalosporins enterobacterales resistance remained stable.</p><p><strong>Conclusions: </strong>The COVID pandemic increased the overall antibiotic consumption, but not the 1000-patients-day consumption in ICUs. However, one of the main effects was to shift usage towards more broad-spectrum antibiotics, which may contribute to growing resistance.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"1-11"},"PeriodicalIF":2.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144755274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Five-year real-world experience with off-label dalbavancin treatment for complex gram-positive infections at a Swedish tertiary hospital.","authors":"Anna Hall, Emeli Månsson, Anders Krifors","doi":"10.1080/23744235.2025.2541853","DOIUrl":"https://doi.org/10.1080/23744235.2025.2541853","url":null,"abstract":"<p><strong>Background: </strong>Dalbavancin is a long-acting lipoglycopeptide approved for acute bacterial skin and soft-tissue infections. Its prolonged half-life enables outpatient treatment, reducing the burden of hospitalisation. Despite increasing off-label use for complex Gram-positive infections, real-world effectiveness data remain limited.</p><p><strong>Objective: </strong>This study aimed to evaluate the clinical effectiveness and safety of dalbavancin in a real-world tertiary care setting in Sweden.</p><p><strong>Methods: </strong>We retrospectively analysed the medical records of all patients (<i>n</i> = 66) who received dalbavancin in Region Västmanland, Sweden, from 2019 to 2023. Patient characteristics, source of infection, identified pathogens, treatment regimens, and outcomes were extracted from medical records. The primary outcome was clinical cure at 6 months; secondary outcomes included mortality, need for suppressive therapy, and adverse events.</p><p><strong>Results: </strong>Sixty-six patients (median age 73 years; 47% female) received dalbavancin for orthopaedic/bone infections (56%), endocarditis (23%), vascular graft infections (6%), bacteraemia (6%), sacral ulcer infections (6%), and other infections (3%). The patients had significant comorbidities: diabetes (38%), malignancy (33%), chronic kidney disease (44%), and substance use disorders (17%).\"Methicillin-susceptible\" Staphylococcus aureus was the predominant pathogen (31% of isolates). Dalbavancin was prescribed to facilitate outpatient therapy (53%), address poor compliance (17%), or manage antibiotic intolerances (17%). Patients received a median of 2 doses (range 1-17). At 6-month follow-up, 62% achieved clinical cure, 18% remained on suppressive therapy, and 20% died, primarily from underlying conditions. Adverse events were infrequent (6%) and generally mild.</p><p><strong>Conclusions: </strong>Dalbavancin achieved a 62% cure rate despite significant comorbidities, offering a safe alternative to inpatient care for elderly, comorbid patients.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"1-7"},"PeriodicalIF":2.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144762497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Avian influenza outbreak in Cambodia: a public health concern.","authors":"Muhammad Abdullah Ali, Alishba Hameed, Umama Alam, Zaryab Bacha, Ahmad Khan, Sangeen Khan","doi":"10.1080/23744235.2025.2540987","DOIUrl":"https://doi.org/10.1080/23744235.2025.2540987","url":null,"abstract":"","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"1-2"},"PeriodicalIF":2.3,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144755273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-Pandemic shifts in peritonsillar abscess: incidence and microbiological trends following the cessation of COVID-19-related nonpharmaceutical interventions.","authors":"Tejs Ehlers Klug, Thomas Lynge Sørensen, Lisa Caulley, Sara Hillerup","doi":"10.1080/23744235.2025.2539285","DOIUrl":"https://doi.org/10.1080/23744235.2025.2539285","url":null,"abstract":"<p><strong>Background: </strong>The impact of COVID-19-related nonpharmaceutical interventions (NPI) on the bacterial composition of upper airway infections remains largely unexplored.</p><p><strong>Objectives: </strong>We aimed to investigate the incidence and microbiology of peritonsillar abscess (PTA) following the cessation of NPI and to compare these findings with the periods before and during NPI implementation.</p><p><strong>Methods: </strong>We performed a cross-sectional analysis of all PTA cases and their microbiological findings from 12 March, 2018 to 11 March, 2024, among patients admitted to the Ear-Nose-Throat Department, Aarhus University Hospital. Patients were categorised into three two-year periods in relation to NPI. Age-stratified population data for the catchment area were sourced from Statistics Denmark.</p><p><strong>Results: </strong>A total of 1,030 patients were included. The annual incidence rate of PTA was significantly higher post-NPI (26.9 cases/100,000) compared to both the NPI period (14.9 cases/100,000, <i>p</i> < 0.001) and the pre-NPI period (21.8 cases/100,000, <i>p</i> = 0.003). Increased post-NPI rates were observed across all age groups. The number of cases positive for <i>Streptococcuspyogenes</i> and <i>Fusobacterium necrophorum</i> increased post-NPI (<i>n</i> = 102 and <i>n</i> = 89, respectively) compared to during the NPI period (<i>n</i> = 28 and <i>n</i> = 64, <i>p</i> < 0.001 and <i>p</i> = 0.052, respectively) and pre-NPI (<i>n</i> = 67 and <i>n</i> = 60, <i>p</i> = 0.009 and <i>p</i> = 0.021, respectively). Statistically non-significant increasing trends were found for less prevalent bacteria.</p><p><strong>Conclusion: </strong>Following NPI cessation, PTA incidence rates surpassed both the NPI and pre-NPI levels. The rising PTA incidence rates post-NPI were primarily driven by an increasing number of cases positive for <i>S. pyogenes</i> and <i>F. necrophorum</i>, suggesting an immunity debt to these prevalent pathogens.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"1-9"},"PeriodicalIF":2.3,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144746299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and outcomes of acute Q fever with and without hepatitis: a retrospective cohort study.","authors":"Mona Mustafa Hellou, Halima Dabaja-Younis, Rabah Yasin, Moran Szwarcwort-Cohen, Nesrin Ghanem-Zoubi","doi":"10.1080/23744235.2025.2533321","DOIUrl":"https://doi.org/10.1080/23744235.2025.2533321","url":null,"abstract":"<p><strong>Background: </strong>Hepatitis is a variably reported manifestation of acute Q fever; however, its clinical implications remain unclear. This study investigates whether hepatitis is associated with distinct clinical features and outcomes compared to cases without hepatitis.</p><p><strong>Methods: </strong>Data from a retrospective, single-centre study of adult patients diagnosed with acute Q fever between January 2018 and December 2023 were analysed. Patients with clinical and laboratory evidence of acute infection, defined by positive phase II IgG serology or Coxiella burnetii RT-PCR were included. Patients were categorised into two groups based on the presence or absence of hepatitis, defined as elevated liver transaminases above the upper normal limit. Descriptive comparisons were conducted between the two groups.</p><p><strong>Results: </strong>116 patients were included, 87 in the hepatitis group and 29 in the non-hepatitis group. The hepatitis group showed a male predominance (66.7%), while the non-hepatitis group had a higher proportion of females (55.2%) (<i>p</i> = 0.03). Fever was more common in the hepatitis group (85.1%) compared to the non-hepatitis group (65.5%) (<i>p</i> = 0.02). A confirmed diagnosis was more frequent in the hepatitis group (62.1% vs. 27.6%) (<i>p</i> < 0.001). A greater proportion of patients in the hepatitis group received appropriate antibiotic treatment (79.3% vs. 44.8%), with earlier initiation. Despite these differences, complication rates were comparable between groups, and no in-hospital mortality was observed.</p><p><strong>Conclusion: </strong>Hepatitis is a common manifestation of acute Q fever and is associated with a higher likelihood of confirmed diagnosis and earlier initiation of appropriate antibiotic treatment. Clinical outcomes remain favourable, even in patients with hepatitis.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting whole killed virus vaccines for pandemic preparedness: is the NIH's H5N1 strategy a step back or a necessary bet?","authors":"Kehinde Oreoluwa Adebiyi, Ademola Aiyenuro, Sarah Oladejo, Adewunmi Akingbola","doi":"10.1080/23744235.2025.2531160","DOIUrl":"https://doi.org/10.1080/23744235.2025.2531160","url":null,"abstract":"","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-screening risk of tuberculosis progression: a three-year retrospective cohort study of asylum seekers in Sweden.","authors":"Joanna Nederby Öhd, Tobias Lindström Battle, Jerker Jonsson, Sara Dahlgren, Supamon Tomacha, Micael Widerström, Helena Nordenstedt, Niclas Winqvist, Maria-Pia Hergens, Knut Lönnroth","doi":"10.1080/23744235.2025.2534166","DOIUrl":"https://doi.org/10.1080/23744235.2025.2534166","url":null,"abstract":"<p><strong>Introduction: </strong>Strategies for tuberculosis (TB) elimination in low-incidence countries involve screening recent migrants from TB-endemic regions for TB infection (TBI) and providing TB preventive treatment (TPT) to individuals with an increased risk of reactivation. This study aimed to determine TB incidence and identify reactivation risk markers in a cohort of asylum seekers in Sweden after screening.</p><p><strong>Method: </strong>We conducted a registry-based retrospective cohort study with a three-year follow-up of asylum seekers receiving post-arrival Interferon Gamma Release Assay (IGRA) screening in three Swedish regions 2015-2019. Medical records, health-examination records, and the national TB disease registry were linked using identification numbers or probabilistic methods. The primary outcome was TB disease more than 90 days post-screening. Explanatory variables included age, sex, IGRA-result (positive/negative), TPT-initiation, and TB incidence in the country of origin. Poisson and Cox regression addressed incidence rates (IR), incidence rate ratios (IRR), and hazard ratios over a three-year follow-up.</p><p><strong>Results: </strong>The cohort included 21 739 individuals and 70 467 person-years. Incident TB disease was recorded in 41 cases (IR 58.2/100 000 person-years). The IR for those with a positive IGRA was 321.7/100 000 person-years (<i>n</i> = 34). The highest risk was in persons aged under 20 with no TPT (1 279.0/100 000 person-years). Positive IGRA result, age under 20 years, and origin from TB-endemic country predicted incident TB.</p><p><strong>Discussion: </strong>Risk markers for incident TB were similar to findings previously reported. However, the observed 0.3% annual reactivation risk found among all IGRA-positive individuals in this study was considerably lower compared to earlier findings.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High one-year mortality following intensive care among adults with influenza A(H1N1)pdm09, A(H3N2), or B in Southern Sweden: a retrospective observational study.","authors":"Nora Jaffer Broman, Anna C Nilsson, Maria Lengquist, Attila Frigyesi, Hans Friberg, Anton Reepalu","doi":"10.1080/23744235.2025.2535443","DOIUrl":"https://doi.org/10.1080/23744235.2025.2535443","url":null,"abstract":"<p><strong>Background: </strong>Influenza ranges from a mild and self-limiting infection to a life-threatening disease with high mortality despite intensive care. Conclusive data on the association between influenza type/subtype and mortality among adults treated at intensive care units (ICU) is lacking.</p><p><strong>Objectives: </strong>To investigate the mortality in adults admitted to ICU with laboratory-confirmed influenza during three consecutive influenza seasons.</p><p><strong>Methods: </strong>This observational multicenter study included adults with PCR-confirmed influenza requiring intensive care at four hospitals in southern Sweden between 2015-2018. The primary outcome was all-cause one-year mortality. Patient characteristics and the impact of influenza type/subtype were studied using Kaplan-Meier and logistic regression analyses.</p><p><strong>Results: </strong>A total of 146 individuals were included: median age 67 years (interquartile range 56-74), 54% were male. Influenza type/subtype was available for 144/146 (99%); A(H1N1)pdm09 in 50 (35%), A(H3N2) in 37 (26%), and B in 57 (40%) patients. Mortality was 19% in the ICU and 32% before hospital discharge. At one year, 43% were diseased, ranging from 36% to 49%, depending on type/subtype (log-rank test <i>p</i> = 0.32). Mortality rates remained similar for all three influenza types/subtypes after adjusting for age, sex, and a modified comorbidity index. Antibiotics were prescribed for 125/145 (86%) within 48 h of ICU admission, with microbiological confirmation of coinfection in 53/125 (42%).</p><p><strong>Conclusions: </strong>Among adults admitted to intensive care with PCR-confirmed influenza, mortality rates were similar independently of influenza type/subtype. Mortality increased from 19% in the ICU to 43% one year after admission, highlighting the importance of monitoring ICU-survivors and reporting long-term outcomes in critically ill influenza patients.</p>","PeriodicalId":73372,"journal":{"name":"Infectious diseases (London, England)","volume":" ","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}